Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMGeS: Mitomycin-C and Gemcitabine Sequential Therapy in BCG-Unresponsive NMIBC
NCT06388720Phase 2Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Nov 2024
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of mitomycin c, gemcitabine in Non-muscle-invasive bladder cancer (NMIBC), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Started Nov 2024; status: recruiting.
02
Drugs
mitomycin cgemcitabine
03
Conditions
Non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT06388720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06388720.